| 000 | 01364 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250516101705.0 | ||
| 264 | 0 | _c20130115 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a2567-5761 | ||
| 024 | 7 |
_a10.5482/ha-1192 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMüller, K A L | |
| 245 | 0 | 0 |
_aElinogrel, an orally and intravenously available ADP-receptor antagonist. How does elinogrel affect a personalized antiplatelet therapy? _h[electronic resource] |
| 260 |
_bHamostaseologie _c2012 |
||
| 300 |
_a191-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPrecision Medicine _xmethods |
| 650 | 0 | 4 |
_aPurinergic P2Y Receptor Antagonists _xadministration & dosage |
| 650 | 0 | 4 |
_aQuinazolinones _xadministration & dosage |
| 650 | 0 | 4 |
_aSulfonamides _xadministration & dosage |
| 650 | 0 | 4 |
_aThrombosis _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGeisler, T | |
| 700 | 1 | _aGawaz, M | |
| 773 | 0 |
_tHamostaseologie _gvol. 32 _gno. 3 _gp. 191-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5482/ha-1192 _zAvailable from publisher's website |
| 999 |
_c21926555 _d21926555 |
||